Table 2.
Clinical results of prostate HDR brachytherapy as monotherapy
| Dose | No. of | Follow-up | PSA control rate/ | Late toxicity ≥ Grade 2a |
||
|---|---|---|---|---|---|---|
| Author [ref.] | fractionation | Patients | (year) | Risk group | Genitourinary | Gastrointestinal |
| Yoshioka [submitted for publication, 21] | 54 Gy/9 Fr. | 112 | 5.4 | 85% (5y)/Low 93% (5y)/Intermediate 79% (5y)/High |
7.1% | 7.1% |
| 45.5 Gy/7 Fr. | 63 | 3.5 | 96% (3y)/Intermediate 90% (3y)/High |
6.3% | 1.6% | |
| Demanes [12] | 42 Gy/6 Fr. | 157 | 5.2 | 97% (5y)/Low–intermediate | 28.9% | <1.0% |
| Martinez [18, 22] | 38 Gy/4 Fr. | 171 | 4.6 | 91% (5y)/Low–intermediate | 40.5% | 2.0% |
| 24 Gy/2 Fr. | 50 | 1.4 | Not available | 25.5% | 5.3% | |
| 27 Gy/2 Fr. | 44 | |||||
| Rogers [11] | 39 Gy/6 Fr. | 284 | 2.7 | 94% (5y)/Intermediate | 7.7% | 0.0% |
| Zamboglou [10] | 38 Gy/4 Fr. | 141 | 4.4 | 95% (5y)/Low 93% (5y)/Intermediate 93% (5y)/High |
27.5% | 2.6% |
| 38 Gy/4 Fr. | 351 | |||||
| 34.5 Gy/3 Fr. | 226 | |||||
| Hoskin [9] | 34 Gy/4 Fr. | 34 | 3.5 | 95% (3y)/Intermediate 87% (3y)/High |
33.0% | 13.0% |
| 36 Gy/4 Fr. | 25 | 40.0% | 4.0% | |||
| 31.5 Gy/3 Fr. | 55 | 34.0% | 7.0% | |||
| Ghadjar [13] | 38 Gy/4 Fr. | 36 | 3 | 100% (3y)/Low–intermediate | 36.1% | 5.6% |
| Barkati [14] | 30 Gy/3 Fr. | 19 | 3.3 | 88% (3y)/Low–intermediate | 59.0% | 5.1% |
| 31.5 Gy/3Fr. | 19 | |||||
| 33 Gy/3 Fr. | 19 | |||||
| 34.5 Gy/3 Fr. | 22 | |||||
| Komiya [16] | 45.5 Gy/7 Fr. | 51 | 1.4 | 100% (2y)/Low–high | 11.8% | 2.0% |
| Prada [17] | 19 Gy/1 Fr. | 40 | 1.6 | 100% (2.7y)/Low 88% (2.7y)/Intermediate |
0.0% | 0.0% |
HDR = high-dose-rate, PSA = prostate-specific antigen, Fr. = fraction(s). aScored per event not per patient.